Science Explorer Back to mapMap

Most cited papers from Eloxx Pharmaceuticals (United States)

What are the most cited papers from Eloxx Pharmaceuticals (United States)?

The most cited paper from Eloxx Pharmaceuticals (United States) is "Cardiac calcification in adult hemodialysis patients" (Paolo Raggi, Amy Boulay, Scott Chasan-Taber et al., 2002), with 1,130 citations. Next come "Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663" (329) and "RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone" (304).

Showing 50 of 61 papers. Every paper with more than 17 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Cardiac calcification in adult hemodialysis patients Paolo Raggi, Amy Boulay, Scott Chasan-Taber et al. · Journal of the American College of Cardiology Open access Feb 2002 1,130
2 Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663 Margaret van Heek, Constance Farley, Douglas S. Compton et al. · British Journal of Pharmacology Open access Apr 2000 329
3 RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K. Burke, Maureen A. Dillon · Kidney International Open access 1999 304
4 Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation Driss El Kebir, Per Gjorstrup, János G. Filep · Proceedings of the National Academy of Sciences Open access 27 Aug 2012 285
5 A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients Anthony J. Bleyer, Steven K. Burke, Maureen A. Dillon et al. · American Journal of Kidney Diseases Apr 1999 277
6 Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure Glenn Matthew Chertow, Steven K. Burke, J. Michael Lazarus et al. · American Journal of Kidney Diseases 1997 249
7 Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia Howard H Knapp, Helmut G. Schrott, Patrick Ma et al. · The American Journal of Medicine Apr 2001 203
8 Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats Kyoko Saito Katsumata, Kenichiro Kusano, Michinori Hirata et al. · Kidney International Open access 8 Jul 2003 164
9 Structural genomics of protein phosphatases Steven C. Almo et al. · Journal of Structural and Functional Genomics Open access Sep 2007 162
10 Outcome of a Workshop on Applications of Protein Models in Biomedical Research Torsten F. Schwede et al. · Structure Open access Feb 2009 154
11 Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia Mario Gennaro Cozzolino, Mark E. Staniforth, Helen Liapis et al. · Kidney International Open access 15 Oct 2003 144
12 Effectiveness of Colesevelam Hydrochloride in Decreasing LDL Cholesterol in Patients With Primary Hypercholesterolemia: A 24-Week Randomized Controlled Trial William Insull, Phillip D. Toth, William S. Mullican et al. · Mayo Clinic Proceedings Oct 2001 140
13 Controlling Herpes Simplex Virus-Induced Ocular Inflammatory Lesions with the Lipid-Derived Mediator Resolvin E1 Naveen K. Rajasagi, Pradeep B. J. Reddy, Amol S. Suryawanshi et al. · The Journal of Immunology Open access 28 Dec 2010 137
14 RnaGel(R), a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers Steven K. Burke, Eduardo Slatopolsky, Dennis Goldberg · Nephrology Dialysis Transplantation Aug 1997 128
15 The Effects of Sevelamer Hydrochloride and Calcium Carbonate on Kidney Calcification in Uremic Rats Mario Gennaro Cozzolino, Adriana Dusso, Helen Liapis et al. · Journal of the American Society of Nephrology Open access Sep 2002 117
16 The Effects of Sevelamer and Calcium Acetate on Proxies of Atherosclerotic and Arteriosclerotic Vascular Disease in Hemodialysis Patients Glenn Matthew Chertow, Paolo Raggi, James T. McCarthy et al. · American Journal of Nephrology 2003 108
17 Effect of RenaGel(R), a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients Dennis Goldberg · Nephrology Dialysis Transplantation Sep 1998 107
18 Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemia Michael H. Davidson, Phillip D. Toth, Stuart R. Weiss et al. · Clinical Cardiology Open access Jun 2001 103
19 Drug Interactions with Colesevelam Hydrochloride, a Novel, Potent Lipid-Lowering Agent Joanne M. Donovan, Daria Stypinski, Mark R. Stiles et al. · Cardiovascular Drugs and Therapy Dec 2000 93
20 Effects of Bedtime Very Low Dose Cyclobenzaprine on Symptoms and Sleep Physiology in Patients with Fibromyalgia Syndrome: A Double-blind Randomized Placebo-controlled Study Harvey Moldofsky, HERBERT W. HARRIS, W. Tad Archambault et al. · The Journal of Rheumatology Open access Sep 2011 92
21 GT160-246, a Toxin Binding Polymer for Treatment of Clostridium difficile Colitis Caroline B. Kurtz, E. Pat Cannon, Alex Brezzani et al. · Antimicrobial Agents and Chemotherapy Open access Aug 2001 88
22 Resolvin E1 (RX-10001) Reduces Corneal Epithelial Barrier Disruption and Protects Against Goblet Cell Loss in a Murine Model of Dry Eye Cintia Sade de Paiva, C. Schwartz, Per Gjorstrup et al. · Cornea 18 Jan 2012 84
23 Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study Vlad Dzavik et al. · European Heart Journal 26 Apr 2007 79
24 Effect of RenaGel(R), a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats David P. Rosenbaum, Stephen R Holmes-Farley, W. Harry Mandeville et al. · Nephrology Dialysis Transplantation May 1997 74
25 Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids Daniel K. Crawford, Jasper Mullenders, Johanna Pott et al. · Journal of Cystic Fibrosis Open access 6 Feb 2021 73
26 Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers Andi Leubitz, Anat Frydman‐Marom, Neal Sharpe et al. · Clinical Pharmacology in Drug Development Open access 16 Jan 2019 72
27 The omega-3 fatty acid-derived neuroprotectin D1 limits hippocampal hyperexcitability and seizure susceptibility in kindling epileptogenesis Alberto E. Musto, Per Gjorstrup, Nicolas Guillermo Bazan · Epilepsia Open access 13 May 2011 72
28 The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat Yusuke Tomita, Min-Jung Lee, Sunmin Lee et al. · OncoImmunology Open access 31 Aug 2016 71
29 The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4 Yan Zang, Sufi Mary Thomas, Elena T. Chan et al. · Autophagy Open access 20 Sep 2012 69
30 Therapeutic uses of antioxidant liposomes William L. Stone, Milton G. Smith · Molecular Biotechnology Open access Jul 2004 65
31 Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment Vijayabhaskar Veeravalli, Ranjeet Prasad Dash, Jennifer A. Thomas et al. · Drug Safety 4 May 2020 63
32 ELX-02 Generates Protein via Premature Stop Codon Read-Through without Inducing Native Stop Codon Read-Through Proteins Daniel K. Crawford, Iris Alroy, Neal Sharpe et al. · Journal of Pharmacology and Experimental Therapeutics Open access 6 May 2020 56
33 Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study Patrick B. Deegan, Özlem Göker-Alpan, Tarekegn Geberhiwot et al. · Molecular Genetics and Metabolism Open access 8 Nov 2022 55
34 A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome Raffaele Badolato et al. · Blood Open access 21 Apr 2024 54
35 Sevelamer, a Phosphate-Binding Polymer, is a Non-Absorbed Compound Melissa A. Plone, John S. Petersen, David P. Rosenbaum et al. · Clinical Pharmacokinetics 2002 54
36 Development and evaluation of a multimodal marker of major depressive disorder Jie Yang et al. · Human Brain Mapping Open access 16 Aug 2018 50
37 Efficacy and Safety of Sublingual Cyclobenzaprine for the Treatment of Fibromyalgia: Results From a Randomized, Double‐Blind, Placebo‐Controlled Trial Seth M. Lederman, Lesley M. Arnold, Ben J Vaughn et al. · Arthritis Care & Research Open access 11 May 2023 48
38 Anti-microRNA-21 Therapy on Top of ACE Inhibition Delays Renal Failure in Alport Syndrome Mouse Models Diana M. Rubel, Joseph Boulanger, Florin L. Craciun et al. · Cells Open access 9 Feb 2022 44
39 Genetics of cystogenesis in base-edited human organoids reveal therapeutic strategies for polycystic kidney disease Courtney E. Vishy, Chardai J. Thomas, Thomas L. Vincent et al. · Cell stem cell Open access Apr 2024 42
40 Novel Cholesterol Lowering Polymeric Drugs Obtained by Molecular Imprinting Chad C. Huval, Mathew J. Bailey, William H. Braunlin et al. · Macromolecules 14 Feb 2001 42
41 Vacuuming the Periplasm Olga Lomovskaya, Maxim M. Totrov · Journal of Bacteriology Open access 2 Mar 2005 40
42 Polymeric metal complex catalyzed enantioselective epoxidation of olefins Pradeep K. Dhal, Binod B. De, Swaminathan Sivaram · Journal of Molecular Catalysis A Chemical Dec 2001 40
43 A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX‐02 in Healthy Subjects Andi Leubitz, Frédéric P. Vanhoutte, Ming‐yi Hu et al. · Clinical Pharmacology in Drug Development Open access 19 Jan 2021 36
44 Sevelamer Hydrochloride (Renagel®), a Nonabsorbed Phosphate‐Binding Polymer, Does Not Interfere with Digoxin or Warfarin Pharmacokinetics Steven K. Burke, Naseem S. Amin, Carlo Incerti et al. · The Journal of Clinical Pharmacology Feb 2001 35
45 The novel aminoglycoside, ELX-02, permits CTNSW138X translational read-through and restores lysosomal cystine efflux in cystinosis Emma J. Brasell, Lee Lee Chu, Murielle M. Akpa et al. · PLoS ONE Open access 4 Dec 2019 34
46 Studies of cholesterol and bile acid metabolism, and early atherogenesis in hamsters fed GT16-239, a novel bile acid sequestrant (BAS) Thomas A. Wilson, Robert J. Nicolosi, Eugene J. Rogers et al. · Atherosclerosis Oct 1998 34
47 Neuronal Nitric Oxide Synthase Contributes to the Regulation of Hematopoiesis Peter A. Krasnov, Tatyana V. Michurina, Michael A. Packer et al. · Molecular Medicine Open access 25 Feb 2008 32
48 Sevelamer Hydrochloride (Renagel®), a Phosphate‐Binding Polymer, Does Not Alter the Pharmacokinetics of Two Commonly Used Antihypertensives in Healthy Volunteers Steven K. Burke, Naseem S. Amin, Carlo Incerti et al. · The Journal of Clinical Pharmacology Feb 2001 27
49 Absorption, Distribution and Excretion of GT31-104, a Novel Bile Acid Sequestrant, in Rats and Dogs After Acute and Subchronic Administration David P. Rosenbaum, John S. Petersen, Sylvie Ducharme et al. · Journal of Pharmaceutical Sciences May 1997 27
50 Determination of the binding parameter constants of Renagel® capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography Ronald A. Swearingen, Xi Chen, John S. Petersen et al. · Journal of Pharmaceutical and Biomedical Analysis Jun 2002 27

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.